Lilly, Novo, and the new terms of the oral obesity market

In the oral GLP-1 class, efficacy parity is increasingly treated as the baseline assumption. Competitive positions are being determined by adherence profile and access architecture, as opposed to weight-loss headline numbers.

Orforglipron: Lilly publishes tolerability data and prepares a Q2 launch

Full results from ACHIEVE-3, a head-to-head Phase 3 trial published February 26 in The Lancet, showed that Eli Lilly's oral GLP-1 candidate orforglipron outperformed Novo Nordisk's Rybelsus on efficacy at the cost of a higher rate of side effects. At the 36 mg dose, orforglipron reduced blood glucose by 2.2% and delivered 9.2% weight loss, against 1.4% and 5.3% for Rybelsus 14 mg. Discontinuation rates were 9.7% for orforglipron against 4.9% for Rybelsus.

Indication may decide whether patients accept that trade-off. In obesity, where weight outcome is the primary motivation, the efficacy gap may be sufficient to offset the tolerability difference. In type 2 diabetes, where Rybelsus has an established prescribing base and long-term adherence is the clinical variable, the discontinuation rate is a more significant number.

On March 2, Reuters reported that Lilly CFO Lucas Montarce, speaking at the TD Cowen healthcare conference, confirmed the company expects an FDA decision in early Q2 and can begin shipping within approximately one week of approval. Lilly has staged $1.5 billion in pre-launch inventory and is negotiating coverage with PBMs. The PBM negotiation remains the variable.

Novo Nordisk and Hims & Hers: distribution dispute resolved as partnership replaces litigation

Bloomberg reported, via Reuters, on March 7, that Novo Nordisk plans to sell its weight-loss drugs through the Hims & Hers platform, ending a legal dispute that had escalated sharply in the preceding weeks. Novo sued Hims in February over patent infringement, after the telehealth company briefly offered a $49 compounded version of Novo's obesity pill before withdrawing it under FDA pressure. A formal announcement was expected as early as March 9; the deal had not been officially confirmed at time of writing.

Novo terminated a distribution agreement with Hims over marketing conduct, sued the company, drew FDA involvement, then moved to a reported partnership structure within weeks. Whether that reflects a change in strategic position or the conclusion of a negotiation, the outcome is the same: a telehealth platform moved from litigation target to distribution partner.

The orforglipron tolerability data and the reported Novo-Hims partnership point toward the same structural shift: in the oral GLP-1 market, adherence profile and distribution reach, rather than efficacy, are increasingly the differentiators.

Subscribe for future analysis and intelligence updates.